Premium
Multiple oral doses of nicardipine, a calcium‐entry blocker: Effects on renal function, plasma renin activity, and aldosterone concentration in mild‐to‐moderate essential hypertension
Author(s) -
Baba T,
Ishizaki T,
Murabayashi S,
Aoyagi K,
Tamasawa N,
Takebe K
Publication year - 1987
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1987.137
Subject(s) - nicardipine , aldosterone , renal blood flow , renal function , plasma renin activity , endocrinology , medicine , essential hypertension , effective renal plasma flow , filtration fraction , blood pressure , urology , chemistry , renin–angiotensin system
We studied the effects of nicardipine administered in a 4‐week fixed oral maintenance dosage (20 or 40 mg t.i.d.) on renal function, plasma renin activity (PRA), and plasma aldosterone concentration in seven patients with mild‐to‐moderate essential hypertension. Glomerular filtration rate and renal blood flow were measured by means of sodium thiosulfate and para‐aminohippurate, respectively. Nicardipine increased renal blood flow by 11.5% ± 4.3% (mean ± SE; P < 0.05) and glomerular filtration rate by 16.3% ± 6.4% (P < 0.05) and decreased total renal vascular resistance by 30.0% ± 2.7% (P < 0.05), with a significant (P < 0.05) reduction in systolic and diastolic blood pressure as compared with placebo values. Nicardipine increased PRA significantly (P < 0.05), whereas plasma aldosterone concentration remained unchanged. Our results indicate that nicardipine given in a multiple oral dosage has some favorable renal effects with a concomitant hypotensive action in patients with mild‐to‐moderate essential hypertension. Nicardipine appears to blunt the secretion of aldosterone responding to an increased PRA possibly through its calcium‐antagonizing action. Clinical Pharmacology and Therapeutics (1987) 42, 232–239; doi: 10.1038/clpt.1987.137